| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
49 companies · Health Care
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | NTRA Natera, Inc. | Sheena Jonathan | Director, CO-FOUNDER | Sell | 4,570 | $198.75 | $908,301.24 | -0.5% | - | - | |
| Mar 18, 2026 | GH Guardant Health, Inc. | Tariq Musa | Director | Sell | 348 | $88.09 | $30,655.32 | -4.0% | - | - | |
| Mar 13, 2026 | NTRA Natera, Inc. | Chapman Rowan E | Director | Sell | 122 | $191.38 | $23,348.36 | -2.1% | - | - | |
| Mar 11, 2026 | TMO Thermo Fisher Scientific Inc. | Shafer Michael D | Executive Vice President | Sell | 1,607 | $499.40 | $802,535.80 | -7.1% | - | - | |
| Mar 10, 2026 | SOLV Solventum Corporation | Wendell Amy McBride | Director | Buy | 1,475 | $68.03 | $100,344.25 | +41.4% | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 5,623 | $204.13 | $1,147,838.17 | -3.5% | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 785 | $204.13 | $160,244.17 | -1.2% | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 915 | $204.13 | $186,781.42 | -0.6% | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | Sheena Jonathan | Director, CO-FOUNDER | Sell | 127 | $204.13 | $25,924.85 | - | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell | 1,745 | $204.13 | $356,211.56 | -0.7% | - | - | |
| Mar 10, 2026 | NTRA Natera, Inc. | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 707 | $204.13 | $144,321.82 | -0.4% | - | - | |
| Mar 9, 2026 | MYGN Myriad Genetics, Inc. | Raha Samraat S. | President and CEO | Buy | 40,000 | $5.00 | $199,844.00 | +8.8% | - | - | |
| Mar 9, 2026 | GRAL GRAIL, Inc. | Freidin Aaron | Chief Financial Officer | Sell | 2,492 | $47.89 | $119,340.41 | -0.4% | - | - | |
| Mar 9, 2026 | GRAL GRAIL, Inc. | RAGUSA ROBERT P | Chief Executive Officer | Sell | 7,203 | $47.93 | $345,239.79 | -1.1% | - | - | |
| Mar 9, 2026 | GRAL GRAIL, Inc. | Ofman Joshua J. | President | Sell | 2,937 | $47.89 | $140,650.22 | -0.3% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.